Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in moderate-to-severe plaque psoriasis
NCT06108544Phase 3Completed
- Sponsor
- Takeda
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Nov 2023; status: completed.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06108544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108544.